Financial Data and Key Metrics Changes - In Q3 2024, the company reported a profit of $40.3 million, or $0.18 per share, with an adjusted profit of $42.5 million, or $0.19 per share, reflecting a decrease of $37.8 million from the previous quarter primarily due to lower time charter earnings [4][5] - Time charter earnings fell from $283 million in the previous quarter to $248 million in Q3 2024 [4] - Operating expenses increased by $3.1 million from the previous quarter, attributed to a decrease in supply rate and costs related to a change in ship management [5] Business Line Data and Key Metrics Changes - The company achieved daily rates of $34,300 for VLCCs, $35,100 for Suezmax, and $31,400 for LR2/Aframax fleets in Q3 2024 [3] - For Q4 2024, 75% of VLCC days are booked at $83,300 per day, 75% of Suezmax days at $60,600, and 51% of LR2/Aframax days at $42,200 [3] Market Data and Key Metrics Changes - Oil in transit has reached record highs, with export volumes increasing, particularly from the Americas and the Atlantic Basin [10] - Year-on-year, Middle Eastern producers' exports are up by 1.2 to 1.3 million barrels per day for October [10] - The company noted logistical challenges around the trade of sanctioned export oil, particularly affecting Lukoil and Rosneft [10] Company Strategy and Development Direction - The company is focusing on maintaining a strong balance sheet and liquidity, with $819 million in cash and cash equivalents as of September 30, 2025 [6] - The fleet consists of 41 VLCCs, 21 Suezmax tankers, and 18 LR2 tankers, all ECO vessels, with a strategy to capitalize on the VLCC-centric trade pattern [6][12] - The company is optimistic about the tanker market's longevity due to limited growth in the compliant tanker fleet and strong oil export fundamentals [20] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the current market developments, indicating a positive outlook for the tanker industry [2] - The company anticipates a sustained contango structure in the oil market, which could lead to inventory builds and increased demand for compliant vessels [12][20] - Management highlighted that the tanker market is experiencing high utilization and strong oil exports, with limited growth in the compliant tanker fleet [20] Other Important Information - The company has no meaningful debt maturities until 2030 and no new building commitments, allowing for flexibility in financial management [6] - The average cash-based breakeven rates for the next 12 months are estimated at approximately $26,000 per day for VLCCs, $23,300 for Suezmax, and $23,600 for LR2 tankers [7][8] Q&A Session Summary Question: Is the company looking to deleverage the balance sheet while maintaining dividends? - Management stated that they are different from peers and are not particularly comfortable with low loan-to-value ratios, indicating a conservative approach to financial management [22][24] Question: How do older ships become less efficient without being scrapped? - Management explained that older vessels face high insurance costs and limited trading options, making them less efficient in the compliant oil market [26][29] Question: What is the outlook for the dark fleet and its impact on the market? - Management noted an increasing number of vessels sitting idle and discussed potential solutions for recycling sanctioned vessels [34][36] Question: How does the current market environment affect vessel demand? - Management indicated that the current market is tight, with no signs of weakness, and highlighted key fundamentals supporting the market [65][70] Question: What is the outlook for Q1 compared to Q4? - Management expressed optimism for Q1, citing strong fundamentals that were not present in Q4 of the previous year [66][70]

Financial Data and Key Metrics Changes - UGI Corporation achieved record-adjusted earnings per share (EPS) of $3.32, exceeding the revised guidance range of $3.00 to $3.15, representing a $0.26 increase from the prior year [4][17] - The company generated approximately $530 million in free cash flow and returned about $320 million to shareholders through dividends [4][21] - The leverage ratio for UGI Corporation was 3.9 times, while AmeriGas stood at 4.9 times, reflecting disciplined debt reduction and improved performance [21][25] Business Line Data and Key Metrics Changes - AmeriGas reported EBIT of $166 million, a 17% increase year-over-year, driven by operational momentum and tax benefits [17][21] - The regulated utilities segment achieved record EBIT of $403 million, up $3 million from the previous year, with a total margin increase of $39 million due to a 10% rise in core market volumes [18] - UGI International's EBIT declined by $9 million to $314 million, impacted by higher income tax expenses and lower margin contributions [19][20] Market Data and Key Metrics Changes - The utility segment added over 11,500 residential heating and commercial customers, increasing the customer base to approximately 967,000 across Pennsylvania, West Virginia, and Maryland [18] - LPG volumes at UGI International decreased by 4%, influenced by structural conservation and customer conversions from LPG to natural gas [20] Company Strategy and Development Direction - UGI is focusing on portfolio optimization to enhance resource utilization in core customer segments, aiming for a long-term EPS growth target of 5-7% [5][24] - The company is investing in critical pipeline infrastructure and new LNG and renewable natural gas facilities to expand revenue-generating capabilities [4][9] - AmeriGas is undergoing operational transformation to improve efficiency and customer service, with a focus on safety and financial discipline [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth outlook for all business lines, expecting low double-digit growth over the planning horizon [34] - The company anticipates continued earnings growth in the midstream and marketing segment, supported by fee-based margins and limited commodity exposure [23] - UGI International is expected to maintain performance in line with the current year, driven by strong margin management and organic growth initiatives [24] Other Important Information - UGI deployed approximately $900 million in capital, primarily in natural gas businesses, to position for future earnings growth [21][22] - The company is committed to maintaining a leverage ratio at or below 3.75 times for UGI Corporation and 4.0 times for AmeriGas to ensure financial flexibility [25] Q&A Session Summary Question: Expectations for midstream and LPG businesses in the five-year plan - Management expects low double-digit growth across all business lines during the planning horizon, with consistent growth rates anticipated [34][35] Question: Update on NDAs and data center activity - Management confirmed ongoing discussions with over 50 counterparties regarding various projects, indicating significant activity in Pennsylvania [37] Question: Comments on potential sale of electric utility and portfolio optimization - Management stated that portfolio optimization remains a continuous focus, evaluating opportunities for value creation through holding or divesting assets [39][40] Question: AmeriGas targets for leverage and growth - Management highlighted opportunities for growth in AmeriGas through operational improvements, with expectations for EBIT growth to continue [44][49] Question: Clarification on tax credits and future expectations - Management confirmed that the bulk of investment tax credits received in fiscal 2025 will not recur, leading to a normalized run rate for future earnings [52][53] Question: Changes in CapEx and shareholder returns - Management indicated that utility CapEx is expected to remain consistent or slightly increase, with a commitment to dividends in the coming years [56]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of $27.5 million, or $0.88 per share, compared to a net loss of $68.2 million, or $2.21 per share, a year ago, primarily due to significant restructuring charges in the previous year [20] - Consolidated sales for Q4 2025 were $319 million, down from $447 million a year ago, mainly due to the divestiture of the SGK business [20] - Consolidated adjusted EBITDA for Q4 2025 was $51.5 million, compared to $58.1 million a year ago, reflecting the impact of the SGK divestiture [21][22] Business Line Data and Key Metrics Changes - The memorialization segment reported revenues of $209.7 million for Q4 2025, up from $196.8 million a year ago, with acquisitions contributing approximately $11 million [23] - The industrial technology segment's revenues decreased to $93 million from $113.9 million a year ago, primarily due to lower sales in the engineering business [25] - The brand solution segment's sales were $16.2 million for Q4 2025, down from $135.9 million a year ago, due to the divestiture of the SGK business [26] Market Data and Key Metrics Changes - The company noted that tariffs have impacted all businesses, but they have successfully mitigated these costs by passing along higher prices [12] - The market response to Propelus, the new company formed from the SGK divestiture, has been favorable, with an EBITDA run rate significantly higher than the $100 million initially assumed [5] Company Strategy and Development Direction - The company aims to simplify its corporate structure, expand in higher growth and margin businesses, and reduce costs, with significant actions taken throughout the year [4] - The divestiture of the warehouse automation unit is expected to provide $230 million, significantly reducing total debt and enhancing the company's ability to pursue strategic initiatives [6][28] - The company is actively evaluating other strategic portfolio opportunities and plans to complete smaller transactions to further simplify its operating structure [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term value creation for shareholders, emphasizing the importance of reducing debt and enhancing the balance sheet [6][17] - The company expects adjusted EBITDA guidance of at least $180 million for fiscal 2026, factoring in the 40% interest in Propelus [17] - Management highlighted the ongoing interest in their proprietary dry battery electrode technology, particularly in the context of solid-state batteries and energy storage solutions [15][40] Other Important Information - The company announced an increase in the quarterly dividend to $0.2505 per share, marking the 32nd consecutive annual dividend increase since becoming publicly traded [29] - The company has appointed Michael Naumann as the new Chairman of the Board, succeeding Alvaro Garcia Tunon [9] Q&A Session Summary Question: Can you talk about the opportunity set regarding solid state and ultra capacitors? - Management confirmed that their dry battery electrode technology applies to various energy storage applications, including ultra capacitors and data center power needs [30] Question: How should we think about M&A and augmenting the technology portfolio? - Management stated that the focus is currently on reducing debt and that strategic initiatives will be evaluated once the debt is in line [31] Question: Are customers less reticent to work with you despite the Tesla lawsuit? - Management indicated that customers are more dependent on market environments rather than being less reticent, with significant opportunities in the European market [33] Question: Can you provide an update on beta testing for the new printhead solution? - Management confirmed that the new printhead solution is in the market, with deliveries starting in December, and highlighted the significant market potential [36] Question: What is the significance of the GS1 certification for the new chip product? - Management explained that GS1 certification standardizes the reading of 2D codes, allowing their technology to operate at speeds that meet retailer demands [41]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15][16] - Non-GAAP EPS for Q4 was $0.21 and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15][16] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates core revenue growth between 3%-5% for fiscal 2026, with expected adjusted EBITDA margin expansion of 300 basis points [11][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to value creation and operational excellence [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and capitalizing on opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on delivering core growth and margin expansion [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][22] Q&A Session Summary Question: Guidance on growth and market conditions - Management noted that the market is expected to grow at 1%-2%, with a focus on delivering results for the full year despite a challenging first half due to capital expenditure slowdowns and government funding impacts [25][26][28] Question: Update on SMS growth and backlog - Management expressed confidence in mid-single-digit growth for SMS, supported by a strong backlog and new leadership driving commercial initiatives [29][30] Question: Insights on customer bases and macro conditions - Management highlighted strength in the pharma sector, with ongoing clarity around projects, while noting some delays in academic and government spending due to the recent government shutdown [39][40] Question: Expectations for M&A and market growth - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions, with a bullish outlook for 2026 [70][71] Question: Performance expectations for automated stores - Management indicated that while the automated stores segment is currently experiencing low single-digit growth, investments in R&D are expected to yield positive results in the long term [72][73]

BJ’s Wholesale Club (NYSE:BJ) Q3 2026 Earnings Call November 21, 2025 08:30 AM ET Company ParticipantsLaura Felice - CFOAng Singh - VP FP&ASteven Zaccone - Director of Equity ResearchNone - Unknown Speaker 2Bill Werner - Executive VPNone - Unknown Speaker 1Bob Eddy - Chairman and CEOConference Call ParticipantsRobbie Owens - AnalystMike Baker - Managing Director and Senior Research AnalystKate McShane - AnalystRupesh Parikh - AnalystPeter Benedict - AnalystPedro Gale - AnalystChuck Grom - AnalystOperatorHel ...

Financial Data and Key Metrics Changes - In Q3 2025, total net revenue reached RMB 1.96 billion, reflecting a 23.9% year-over-year increase but a 13.7% decline sequentially from Q2 [6][14] - Income from operations was RMB 331.9 million, down 29.9% year-over-year and 46.4% sequentially, primarily due to higher provisions for credit losses [14] - Net income was RMB 421.2 million, up 12.1% year-over-year but down 20.2% sequentially [14] - The delinquency rates increased, with the 31-60 day delinquency rate rising to 1.85% from 1.16% in Q2 and 1.02% a year ago [7][14] Business Line Data and Key Metrics Changes - The company facilitated and originated RMB 33.64 billion in loans, an 18.7% increase year-over-year but a 13.7% decline sequentially [4][10] - The outstanding loan balance at the end of the quarter was RMB 62.83 billion, up 37.3% from the previous year [10] - Approximately 3.48 million loans were facilitated, representing a 32% increase year-over-year, with an average loan size of RMB 9,654 [10] Market Data and Key Metrics Changes - The active borrower base was approximately 2.44 million, down 14.4% sequentially but up 24.2% year-over-year [10] - The regulatory environment remains stringent, with a focus on consumer protection and responsible lending practices [9] Company Strategy and Development Direction - The company is prioritizing asset quality and risk management over short-term volume expansion, reflecting a strategic shift in response to regulatory pressures [4][9] - There is a commitment to maintaining a compliance-first mindset and adapting to evolving regulatory standards [9][10] - The focus is on cost efficiency and disciplined execution to ensure long-term value preservation [12] Management's Comments on Operating Environment and Future Outlook - Management expects challenges to persist in the coming quarters but remains confident in the company's ability to navigate these with prudence [18] - The outlook for Q4 2025 anticipates total loan facilitation in the range of RMB 21 billion to RMB 23 billion, reflecting a measured pace of origination [17] - Management acknowledges the potential for continued pressure on industry pricing and profitability due to regulatory changes [9][10] Other Important Information - The company repurchased approximately $67.9 million in shares under its buyback program, with about $48 million remaining under the existing plan [16][26] - The balance sheet remains strong, with total assets at RMB 14.69 billion, up 26.4% year-over-year [15] Q&A Session Summary Question: What is the expected take rate for Q4 given the current risk situation? - Management indicated that the new regulatory regime will likely have a material negative impact on volume, margin, and profitability, making it premature to discuss specific take rates [24][25] Question: Is the company considering returning more capital to shareholders? - Management confirmed that capital return remains a key strategy, with ongoing share repurchases and a commitment to maintaining dividends despite industry pressures [26][27] Question: How does management view the regulatory environment going into early 2026? - Management expressed uncertainty about future regulatory actions but emphasized a focus on compliance and consumer protection [32] Question: Can management provide more details on the uptick in delinquencies? - Management acknowledged the increase in delinquencies due to broader economic challenges and indicated that they expect the delinquency rate to continue climbing in the short term [33][34]

BJ’s Wholesale Club (NYSE:BJ) Q3 2026 Earnings Call November 21, 2025 08:30 AM ET Company ParticipantsLaura Felice - CFOAng Singh - VP FP&ASteven Zaccone - Director of Equity ResearchNone - Unknown Speaker 2Bill Werner - Executive VPNone - Unknown Speaker 1Bob Eddy - Chairman and CEOConference Call ParticipantsRobbie Owens - AnalystMike Baker - Managing Director and Senior Research AnalystKate McShane - AnalystRupesh Parikh - AnalystPeter Benedict - AnalystPedro Gale - AnalystChuck Grom - AnalystOperatorHel ...

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5] - The company has secured a contract for silicon-28 and aims to fulfill customer orders by 2026 [4] Company Strategy and Development Direction - The company aims to diversify its operations beyond South Africa and expand its radiopharmaceutical footprint globally [70] - Quantum Leap Energy (QLE) plans to secure the nuclear supply chain and has raised $64.3 million via convertible notes to support its initiatives [13][14] - The acquisition of Skyline Builders is part of a strategy to secure critical material supply chains essential for the U.S. and ASP Isotopes [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the enrichment processes [38] - The focus for the next six months includes completing the Renergen acquisition and achieving operational de-risking by the end of Q1 2026 [39][40] - The company is committed to providing further guidance on revenue projections as clarity improves internally [52][53] Other Important Information - The company is planning to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][50][52] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns of capital commitments and revenue opportunities will be provided in future updates [54][55] Question: Can you discuss the opportunity for LEU Plus? - LEU Plus is a new focus based on customer inquiries, aimed at increasing power density and extending the life of existing nuclear power plants [56][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift away from construction [64][66]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31][32] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [31][32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32][33] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4][5] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5][6] - The company is expanding its radiopharmaceutical operations globally, with the first purchase in the U.S. announced for East Coast Nuclear in Florida [10] Company Strategy and Development Direction - The company aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes, with recent acquisitions supporting this strategy [21][22] - Quantum Leap Energy (QLE) plans to produce lithium-7 and lithium-6 isotopes to meet the growing demand in the nuclear industry [15][16] - The company is focused on operational de-risking and plans to complete the Renergen acquisition and IPO of QLE in the near future [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the silicon-28 enrichment process [38] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49][50] Other Important Information - The company has raised $64.3 million via convertible notes, bringing pro forma cash on hand to $81.6 million [13] - The company is planning to construct new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29][30] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December 2025, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Can you discuss the revenue opportunity for Ytterbium-176 and Silicon-28? - The company is maintaining previous revenue guidance of $50-$70 million for 2026 and 2027 [49][50] Question: What is the capital commitment for building new facilities in 2026? - Detailed capital commitment information will be provided in future updates [54][55] Question: Can you elaborate on the LEU Plus opportunity? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, aimed at increasing power density and extending the life of nuclear power plants [56][60] Question: Should the $3 million revenue from Skyline Builders be modeled going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift to securing the nuclear supply chain [64][66]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year, and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15] - Non-GAAP EPS for Q4 was $0.21, and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17][18] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with expectations of a decline of approximately 1%-2% in Q1 due to capital expenditure slowdowns and government shutdown impacts [21][60] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - Strategic priorities include embedding ABS deeper across the organization, optimizing capital deployment, and continuing to deliver core growth and margin expansion [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customers consolidating partners and investing in automation [9][10] - The company is well-positioned for fiscal 2026, with a focus on operational excellence and a strong balance sheet to support growth initiatives [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the market is expected to grow at 1-2%, with capital expenditure slowdowns impacting growth, particularly in the U.S. [25][26] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent investments in commercial initiatives [29][30] Question: Insights on macroeconomic trends affecting customer bases - Management highlighted strength in pharma spending, with some projects being put on hold but showing signs of recovery [38][40] Question: Expectations for M&A activity - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [69][70]